Blomberg Björn A, Høilund-Carlsen Poul Flemming
Department of Nuclear Medicine, Odense University Hospital, Søndre Boulevard 29, 5000 Odense, Denmark; Department of Radiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Department of Nuclear Medicine, Odense University Hospital, Søndre Boulevard 29, 5000 Odense, Denmark.
PET Clin. 2015 Jan;10(1):1-7. doi: 10.1016/j.cpet.2014.09.001. Epub 2014 Nov 22.
[(18)F]-fluorodeoxyglucose PET ((18)FDG PET) imaging has emerged as a promising tool for assessment of atherosclerosis. By targeting atherosclerotic plaque glycolysis, a marker for plaque inflammation and hypoxia, (18)FDG PET can assess plaque vulnerability and potentially predict risk of atherosclerosis-related disease, such as stroke and myocardial infarction. With excellent reproducibility, (18)FDG PET can be a surrogate end point in clinical drug trials, improving trial efficiency. This article summarizes key findings in the literature, discusses limitations of (18)FDG PET imaging of atherosclerosis, and reports recommendations to optimize imaging protocols.
[18F]氟脱氧葡萄糖正电子发射断层显像（[18F]FDG PET）成像已成为评估动脉粥样硬化的一种有前景的工具。通过靶向动脉粥样硬化斑块糖酵解（一种斑块炎症和缺氧的标志物），[18F]FDG PET可以评估斑块易损性，并有可能预测动脉粥样硬化相关疾病（如中风和心肌梗死）的风险。由于具有出色的可重复性，[18F]FDG PET可以作为临床药物试验的替代终点，提高试验效率。本文总结了文献中的关键发现，讨论了[18F]FDG PET动脉粥样硬化成像的局限性，并报告了优化成像方案的建议。
